Palavras-chave
Fármacos pró-arrítmicos
Risco cardiovascular
Infarto do miocárdio
Efeitos adversos de medicamentos
Como Citar
Resumo
O infarto agudo do miocárdio (IAM) é uma condição clínica grave caracterizada pela interrupção do fluxo sanguíneo para o coração, resultando em dano ao músculo cardíaco. Entre os principais fármacos que podem gerar risco de IAM estão os anti-inflamatórios não esteroides (AINEs), especialmente em uso prolongado e em doses elevadas. Além disso, certos medicamentos para tratar transtornos psiquiátricos, como antidepressivos e antipsicóticos, têm sido associados a distúrbios metabólicos que aumentam a suscetibilidade a doenças cardiovasculares. Os contraceptivos orais, particularmente aqueles contendo estrogênio, também estão ligados a um aumento do risco de trombose e, consequentemente, de IAM, especialmente em mulheres com predisposição a problemas cardiovasculares. Fármacos utilizados para tratar distúrbios hormonais, como algumas terapias de reposição hormonal, podem agravar fatores de risco como hipertensão e dislipidemia. A avaliação cuidadosa da necessidade de uso de tais medicamentos, a escolha de alternativas mais seguras e o monitoramento rigoroso são medidas essenciais para minimizar o risco de IAM associado ao uso de fármacos. Observando a importância do tema que este artigo teve como objetivo Identificar as classes os fármacos que podem contribuir como fatores de risco para o infarto agudo do miocárdio, visando fornecer informações que ajudem na prevenção e manejo adequado dessas medicações em pacientes com predisposição a eventos cardiovasculares, visando fornecer subsídios para a elaboração de estratégias preventivas e terapêuticas mais seguras e eficazes. A metodologia usada foi uma revisão da literatura com base nas obras digitais disponíveis em plataformas digitais confiáveis. Para tanto concluímos que o futuro da farmacoterapia cardiovascular deve se concentrar na prevenção e manejo cuidadoso da cardiotoxicidade, com o objetivo de melhorar os resultados clínicos e a segurança dos pacientes.
Referências
Ahmad, R. S., Hussain, M. B., Sultan, M. T., Arshad, M. S., Waheed, M., Shariati, M. A., ... & Hashempur, M. H. (2020). Biochemistry, safety, pharmacological activities, and clinical applications of turmeric: a mechanistic review. Evidence‐Based Complementary and Alternative Medicine, 2020(1), 7656919.
Akinola, P. S., Tardif, I., & Leclerc, J. (2023). Antipsychotic-induced metabolic syndrome: a review. Metabolic Syndrome and Related Disorders, 21(6), 294-305.
Alanazi, A., Alghanim, M. H., Alamer, A. J., Alshaqaqiq, M. A., Al Busaeed, M. M., Alahmed, A. H., ... & Althagafi, M. A. (2020). Acute myocardial infarction patients’ knowledge regarding the modifiable risk factors of heart disease. International Journal of Pharmaceutical Research and Allied Sciences, 9(2-2020), 210-216.
Alqdwah‐Fattouh, R., Rodríguez‐Martín, S., de Abajo, F. J., González‐Bermejo, D., Gil, M., García‐Lledó, A., & Bolúmar, F. (2020). Differential effects of antidepressant subgroups on risk of acute myocardial infarction: A nested case–control study. British Journal of Clinical Pharmacology, 86(10), 2040-2050.
Anjos, M., Fontes-Oliveira, M., Costa, V. M., Santos, M., & Ferreira, R. (2021). An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life sciences, 280, 119760.
Baldetti, L., Melillo, F., Moroni, F., Gallone, G., Pagnesi, M., Venuti, A., ... & Cappelletti, A. M. (2020). Meta-analysis comparing P2Y12 inhibitors in acute coronary syndrome. The American journal of cardiology, 125(12), 1815-1822.
Beurskens, D. M., Huckriede, J. P., Schrijver, R., Hemker, H. C., Reutelingsperger, C. P., & Nicolaes, G. A. (2020). The anticoagulant and nonanticoagulant properties of heparin. Thrombosis and haemostasis, 120(10), 1371-1383.
Boarescu, P. M., Boarescu, I., Bulboacă, A. E., Bocșan, I. C., Pop, R. M., Gheban, D., ... & Bolboacă, S. D. (2021). Multi-organ protective effects of curcumin nanoparticles on drug-induced acute myocardial infarction in rats with type 1 diabetes mellitus. Applied Sciences, 11(12), 5497.
Bryniarski, P., Nazimek, K., & Marcinkiewicz, J. (2022). Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. International Journal of Molecular Sciences, 23(3), 1772.
Cardinale, D. M., Zaninotto, M., Cipolla, C. M., Passino, C., Plebani, M., & Clerico, A. (2021). Cardiotoxic effects and myocardial injury: The search for a more precise definition of drug cardiotoxicity. Clinical Chemistry and Laboratory Medicine (CCLM), 59(1), 51-57.
Chi, G. C., Kanter, M. H., Li, B. H., Qian, L., Reading, S. R., Harrison, T. N., ... & Reynolds, K. (2020). Trends in acute myocardial infarction by race and ethnicity. Journal of the American Heart Association, 9(5), e013542.
Costa, V. M., Grando, L. G. R., Milandri, E., Nardi, J., Teixeira, P., Mladěnka, P., ... & OEMONOM. (2022). Natural sympathomimetic drugs: From pharmacology to toxicology. Biomolecules, 12(12), 1793.
Dai, H., Much, A. A., Maor, E., Asher, E., Younis, A., Xu, Y., ... & Bragazzi, N. L. (2022). Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990–2017: results from the Global Burden of Disease Study 2017. European Heart Journal-Quality of Care and Clinical Outcomes, 8(1), 50-60.
Delbaere, Q., Chapet, N., Huet, F., Delmas, C., Mewton, N., Prunier, F., ... & Roubille, F. (2023). Anti-inflammatory drug candidates for prevention and treatment of cardiovascular diseases. Pharmaceuticals, 16(1), 78.
Do, U. (2023). Adverse reactions to antiarrhythmic drugs. Cardiovascular Prevention and Pharmacotherapy, 5(1), 1-14.
Dorward, J., Gbinigie, O., Cai, T., Roberts, N. W., Garrett, N., Hayward, G., & Butler, C. C. (2020). The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review. Antiviral therapy, 25(7), 365-376.
Dzherieva, I. S., Volkova, N. I., Davidenko, I. Y., Reshetnikov, I. B., Brovkina, S. S., Avakova, S. M., & Tishchenko, Y. V. (2022). Glucocorticoid therapy is a risk factor for cardiovascular diseases. Medical Herald of the South of Russia, 13(3), 93-106.
Economopoulou, P., Kotsakis, A., Kapiris, I., & Kentepozidis, N. (2015). Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer management and research, 133-143.
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., ... & Kaye, A. M. (2021). Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurology international, 13(3), 387-401.
Fathima, S. N. (2021). An Update on Myocardial Infarction. Current Research and Trends in Medical Science and Technology, 1.
Fuggle, N. R., Cooper, C., Harvey, N. C., Al-Daghri, N., Brandi, M. L., Bruyère, O., ... & Reginster, J. Y. (2020). Assessment of cardiovascular safety of anti-osteoporosis drugs. Drugs, 80, 1537-1552.
Gagnon, L. R., Sadasivan, C., Perera, K., & Oudit, G. Y. (2022). Cardiac complications of common drugs of abuse: pharmacology, toxicology, and management. Canadian Journal of Cardiology, 38(9), 1331-1341.
Giglio, R. V., Papanas, N., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, I., ... & Rizzo, M. (2022). An update on the current and emerging use of thiazolidinediones for type 2 diabetes. Medicina, 58(10), 1475.
Gong, F. F., Vaitenas, I., Malaisrie, S. C., & Maganti, K. (2021). Mechanical complications of acute myocardial infarction: a review. JAMA cardiology, 6(3), 341-349.
Jortveit, J., Pripp, A. H., Langørgen, J., & Halvorsen, S. (2020). Incidence, risk factors and outcome of young patients with myocardial infarction. Heart, 106(18), 1420-1426.
Kalyani, R. R. (2021). Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes. New England Journal of Medicine, 384(13), 1248-1260.
Kamani, M., Akgor, U., & Gültekin, M. (2022). Review of the literature on combined oral contraceptives and cancer. ecancermedicalscience, 16.
Kang, D. O., An, H., Park, G. U., Yum, Y., Park, E. J., Park, Y., ... & Choi, C. U. (2020). Cardiovascular and bleeding risks associated with nonsteroidal anti-inflammatory drugs after myocardial infarction. Journal of the American College of Cardiology, 76(5), 518-529.
Khan, J., Al Asoom, L. I., Al Sunni, A., Rafique, N., Latif, R., Al Saif, S., ... & Borgio, J. F. (2021). Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomedicine & pharmacotherapy, 139, 111557.
Kumar, A., Rathor, K., Vaddi, S., Patel, D., Vanjarapu, P., & Maddi, M. (2022, August). ECG Based Early Heart Attack Prediction Using Neural Networks. In 2022 3rd International Conference on Electronics and Sustainable Communication Systems (ICESC) (pp. 1080-1083). IEEE.
Lamb, Y. N. (2020). Rosuvastatin/ezetimibe: a review in hypercholesterolemia. American journal of cardiovascular drugs, 20, 381-392.
Mamoshina, P., Rodriguez, B., & Bueno-Orovio, A. (2021). Toward a broader view of mechanisms of drug cardiotoxicity. Cell Reports Medicine, 2(3).
McDonagh, M. S., Dana, T., Selph, S., Devine, E. B., Cantor, A., Bougatsos, C., ... & Haupt, D. W. (2020). Updating the comparative evidence on second‐generation antipsychotic use with schizophrenia. Psychiatric Research and Clinical Practice, 2(2), 76-87.
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., ... & Kathrine Skibelund, A. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 42(36), 3599-3726.
Moore, N. (2020). Coronary risks associated with diclofenac and other NSAIDs: an update. Drug safety, 43(4), 301-318.
Mortensen, M. B., & Nordestgaard, B. G. (2020). Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. The Lancet, 396(10263), 1644-1652.
Münzel, T., Hahad, O., Sørensen, M., Lelieveld, J., Duerr, G. D., Nieuwenhuijsen, M., & Daiber, A. (2022). Environmental risk factors and cardiovascular diseases: a comprehensive expert review. Cardiovascular research, 118(14), 2880-2902.
Nair, H. (2020). Cardiac drugs. In Toxicology Cases for the Clinical and Forensic Laboratory (pp. 195-202). Academic Press.
Nitroglycerin-Symposion, H. (2020). Nitroglycerin 9: Nitrates and Mobility. 9th Hamburg Symposium. Walter de Gruyter GmbH & Co KG.
Ornello, R., Canonico, M., Merki-Feld, G. S., Kurth, T., Lidegaard, Ø., MacGregor, E. A., ... & Sacco, S. (2020). Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Expert review of neurotherapeutics, 20(4), 313-317.
Palsøe, M. K., Hansen, C. J., Torp-Pedersen, C., Winkel, B. G., Linnet, K., Tfelt-Hansen, J., & Banner, J. (2024). Proarrhythmic drugs, drug levels, and polypharmacy in victims of sudden arrhythmic death syndrome: An autopsy-based study from Denmark. Heart Rhythm.
Pratiwi, R., Noviana, E., Fauziati, R., Carrão, D. B., Gandhi, F. A., Majid, M. A., & Saputri, F. A. (2021). A review of analytical methods for codeine determination. Molecules, 26(4), 800.
Pugliese, A. M., Coppi, E., Cherchi, F., & Pepeu, G. (2020). Cardiovascular adverse effects of psychotropic drugs. Brain and Heart Dynamics, 707-720.
Rajagopalan, S., & Landrigan, P. J. (2021). Pollution and the heart. New England Journal of Medicine, 385(20), 1881-1892.
Sagris, M., Antonopoulos, A. S., Theofilis, P., Oikonomou, E., Siasos, G., Tsalamandris, S., ... & Tousoulis, D. (2022). Risk factors profile of young and older patients with myocardial infarction. Cardiovascular research, 118(10), 2281-2292.
Salim, H., & Jones, A. M. (2022). Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions. British Journal of Clinical Pharmacology, 88(11), 4812-4827.
Samsky, M. D., Morrow, D. A., Proudfoot, A. G., Hochman, J. S., Thiele, H., & Rao, S. V. (2021). Cardiogenic shock after acute myocardial infarction: a review. Jama, 326(18), 1840-1850.
Sessa, M., Mascolo, A., Dalhoff, K. P., & Andersen, M. (2020). The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine. Expert Opinion on Drug Safety, 19(3), 349-357.
Trapali, M. I. (2023). Therapeutic Uses of Aspirin. In Pain Management-From Acute to Chronic and Beyond. IntechOpen.
Trombini, C., Blasco, J., & Hampel, M. (2020). Ibuprofen and diclofenac: effects on freshwater and marine aquatic organisms–are they at risk?. Non-steroidal anti-inflammatory drugs in water: emerging contaminants and ecological impact, 161-189.
Vrablik, M., Corsini, A., & Tůmová, E. (2022). Beta-blockers for atherosclerosis prevention: a missed opportunity?. Current Atherosclerosis Reports, 24(3), 161-169.
Wayangankar, S. A., Patel, B. C., Parekh, H. D., Holter, J. L., & Lazzara, R. (2015). High-dose cytosine arabinoside-induced symptomatic bradycardia. Journal of Cardiovascular Medicine, 16, S38-S41.
Yang, J., Biery, D. W., Singh, A., Divakaran, S., DeFilippis, E. M., Wu, W. Y., ... & Blankstein, R. (2020). Risk factors and outcomes of very young adults who experience myocardial infarction: the partners YOUNG-MI registry. The American journal of medicine, 133(5), 605-612.
Yang, Y., Gu, B., & Xu, X. Y. (2023). In silico study of different thrombolytic agents for fibrinolysis in acute ischemic stroke. Pharmaceutics, 15(3), 797.
Younis, A., Matetzky, S., Mulla, W., Masalha, E., Afel, Y., Chernomordik, F., ... & Beigel, R. (2020). Epidemiology characteristics and outcome of patients with clinically diagnosed acute myocarditis. The American Journal of Medicine, 133(4), 492-499.
Zaccara, G., Lattanzi, S., & Brigo, F. (2022). Cardiac adverse effects of antiseizure medications. Expert Opinion on Drug Safety, 21(5), 641-652.
Zhu, X., & Cao, G. (2020). Safety of glycoprotein IIb-IIIa inhibitors used in stroke-related treatment: a systematic review and meta-analysis. Clinical and Applied Thrombosis/Hemostasis, 26, 1076029620942594.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Jane Tavares Saraiva, Omero Martins Rodrigues Junior